Drug intelligence / Profile preview

Xiao Liu Tang

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Xiao Liu Tang (XLT), also known as Dang Gui Tail Combination, is a traditional Chinese medicine (TCM) formula. It is primarily studied for its anti-tumor effects, particularly in suppressing the progression of cervical cancer by inducing apoptosis and inhibiting cell migration. Additionally, it has shown promise in alleviating endometriosis-related symptoms, exhibiting anti-inflammatory and pro-apoptotic properties. The formula is designed to promote blood circulation, dissipate stasis, clear collaterals, resolve phlegm, soften masses, soothe the liver, regulate Qi, and invigorate the spleen and kidney.

Brand names: Dang Gui Tail Combination
Other names: 消瘤汤Xiaoshengliu Tang

Targets

CASP3 (Caspase-3)CASP8 (Caspase-8)

Beyond the preview

Go deeper on Xiao Liu Tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiao Liu Tang.

Explore the full profile